HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 55745

HXB2 Location  Gag(263-272)   Gag Epitope Map
View variants at this location
Epitope KRWIILGLNK   Epitope Alignment
Variants
KkWIILGLNK   diminished HLA binding or increased off-rate; replicative capacity reduced
KRWIImGLNK   replicative capacity is not abrogated
KkWIImGLNK   diminished HLA binding or increased off-rate; replicative capacity reduced
KtWIILGLNK   diminished HLA binding or increased off-rate; replicative capacity is not abrogated
KtWIImGLNK   diminished HLA binding or increased off-rate; replicative capacity is not abrogated
KqWIILGLNK   diminished HLA binding or increased off-rate; replicative capacity is not abrogated
KqWIImGLNK   diminished HLA binding or increased off-rate; replicative capacity is not abrogated
KgWIILGLNK   replicative capacity is not abrogated
{a...}KkWIImGLNK   diminished HLA binding or increased off-rate; replicative capacity is not abrogated
{t...}KtWIImGLNK   diminished HLA binding or increased off-rate; replicative capacity is not abrogated
{d**}KRWIILGLNK   replicative capacity is not abrogated
{d**}KgWIILGLNK   diminished HLA binding or increased off-rate; replicative capacity reduced
{d**}KgWIImGLNK   replicative capacity reduced
{d**}KkWIILGLNK   diminished HLA binding or increased off-rate; replicative capacity reduced
Epitope Name KK10
Species (MHC/HLA human(B*27:05)

Variant Details

Showing all: 14 variant(s).


Variant ID.  1596
Epitope Seq.  KRWIILGLNK
Variant Seq.  KkWIILGLNK
Mutations R/K
Epitope Location R2K
HXB2 Location R264K
Mutation Type DHB: diminished HLA binding or increased off-rate
RCR: replicative capacity reduced
Method HLA binding, Relative replication capacity assay
Note This R264K mutation, which is not seen in vivo, abrogates replicative capacity of the virus. Decreased HLA-B27 binding results. Increased infectivity is seen when treated with Cyclosporin A.


Variant ID.  1597
Epitope Seq.  KRWIILGLNK
Variant Seq.  KRWIImGLNK
Mutations L/M
Epitope Location L6M
HXB2 Location L268M
Mutation Type RCOK: replicative capacity is not abrogated
Method HLA binding, Relative replication capacity assay
Note This natural L268M mutation does not affect replicative capacity of the virus or binding to HLA-B27. A decrease in the influence of Cyclosporin A is seen on infectivity.


Variant ID.  1598
Epitope Seq.  KRWIILGLNK
Variant Seq.  KkWIImGLNK
Mutations R/K L/M
Epitope Location R2K L6M
HXB2 Location R264K L268M
Mutation Type DHB: diminished HLA binding or increased off-rate
RCR: replicative capacity reduced
Method HLA binding, Relative replication capacity assay
Note This natural R264K, L268M mutation abrogates replicative capacity of the virus. Decreased HLA-B27 binding results. Increased infectivity is seen when treated with Cyclosporin A.


Variant ID.  1599
Epitope Seq.  KRWIILGLNK
Variant Seq.  KtWIILGLNK
Mutations R/T
Epitope Location R2T
HXB2 Location R264T
Mutation Type DHB: diminished HLA binding or increased off-rate
RCOK: replicative capacity is not abrogated
Method HLA binding, Relative replication capacity assay
Note This natural R264T mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A.


Variant ID.  1600
Epitope Seq.  KRWIILGLNK
Variant Seq.  KtWIImGLNK
Mutations R/T L/M
Epitope Location R2T L6M
HXB2 Location R264T L268M
Mutation Type DHB: diminished HLA binding or increased off-rate
RCOK: replicative capacity is not abrogated
Method HLA binding, Relative replication capacity assay
Note This natural R264T, L268M double mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A.


Variant ID.  1601
Epitope Seq.  KRWIILGLNK
Variant Seq.  KqWIILGLNK
Mutations R/Q
Epitope Location R2Q
HXB2 Location R264Q
Mutation Type DHB: diminished HLA binding or increased off-rate
RCOK: replicative capacity is not abrogated
Method HLA binding, Relative replication capacity assay
Note This R264Q variant is not seen in vivo, and does not affect replicative capacity. Severely decreased HLA-B27 binding does, however, result with decrease in infectivity when treated with Cyclosporin A.


Variant ID.  1602
Epitope Seq.  KRWIILGLNK
Variant Seq.  KqWIImGLNK
Mutations R/Q L/M
Epitope Location R2Q L6M
HXB2 Location R264Q L268M
Mutation Type DHB: diminished HLA binding or increased off-rate
RCOK: replicative capacity is not abrogated
Method HLA binding, Relative replication capacity assay
Note This natural R264Q, L268M double mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A.


Variant ID.  1603
Epitope Seq.  KRWIILGLNK
Variant Seq.  KgWIILGLNK
Mutations R/G
Epitope Location R2G
HXB2 Location R264G
Mutation Type RCOK: replicative capacity is not abrogated
Method HLA binding, Relative replication capacity assay
Note This natural R264G mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A.


Variant ID.  2311
Epitope Seq.  {S...}KRWIILGLNK
Variant Seq.  {a...}KkWIImGLNK
Mutations R/K L/M S/A
Epitope Location R2K L6M S-90A
HXB2 Location R264K L268M S173A
Mutation Type DHB: diminished HLA binding or increased off-rate
RCOK: replicative capacity is not abrogated
Method HLA binding, Relative replication capacity assay
Note This triple S173A, R264K , L268M natural mutation does not affect replicative capacity of the virus, and brings its activity back to that of wild type. Decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A.


Variant ID.  2312
Epitope Seq.  {S...}KRWIILGLNK
Variant Seq.  {t...}KtWIImGLNK
Mutations R/T L/M S/T
Epitope Location R2T L6M S-90T
HXB2 Location R264T L268M S173T
Mutation Type DHB: diminished HLA binding or increased off-rate
RCOK: replicative capacity is not abrogated
Method HLA binding, Relative replication capacity assay
Note This natural S173T, R264T, L268M triple mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results.


Variant ID.  2313
Epitope Seq.  {E**}KRWIILGLNK
Variant Seq.  {d**}KRWIILGLNK
Mutations E/D
Epitope Location E-3D
HXB2 Location E260D
Mutation Type RCOK: replicative capacity is not abrogated
Method HLA binding, Relative replication capacity assay
Note This natural, upstream E260D mutation increases replicative capacity and retains binding to HLA-B27. Decreased infectivity is seen when treated with Cyclosporin A.


Variant ID.  2314
Epitope Seq.  {E**}KRWIILGLNK
Variant Seq.  {d**}KgWIILGLNK
Mutations R/G E/D
Epitope Location R2G E-3D
HXB2 Location R264G E260D
Mutation Type DHB: diminished HLA binding or increased off-rate
RCR: replicative capacity reduced
Method HLA binding, Relative replication capacity assay
Note This natural E260D, R264G double mutation does not affect replicative capacity. Severely decreased HLA-B27 binding results. Decreased infectivity is seen when treated with Cyclosporin A.


Variant ID.  2315
Epitope Seq.  {E**}KRWIILGLNK
Variant Seq.  {d**}KgWIImGLNK
Mutations R/G E/D L/M
Epitope Location R2G E-3D L6M
HXB2 Location R264G E260D L268M
Mutation Type RCR: replicative capacity reduced
Method HLA binding, Relative replication capacity assay
Note This E260D, R264G, L268M triple mutation greatly affects replicative capacity. It is not seen in vivo.


Variant ID.  2316
Epitope Seq.  {E**}KRWIILGLNK
Variant Seq.  {d**}KkWIILGLNK
Mutations R/K E/D
Epitope Location R2K E-3D
HXB2 Location R264K E260D
Mutation Type DHB: diminished HLA binding or increased off-rate
RCR: replicative capacity reduced
Method HLA binding, Relative replication capacity assay
Note This E260D, R264K double mutation is not found in vivo and greatly affects replicative capacity. Decreased HLA-B27 binding results.

References

Schneidewind2008 Arne Schneidewind, Mark A Brockman, John Sidney, Yaoyu E Wang, Huabiao Chen, Todd J Suscovich, Bin Li, Rahma I Adam, Rachel L Allgaier, Bianca R Mothé, Thomas Kuntzen, Cesar Oniangue-Ndza, Alicja Trocha, Xu G Yu, Christian Brander, Alessandro Sette, Bruce D Walker, and Todd M Allen. Structural and Functional Constraints Limit Options for Cytotoxic T-Lymphocyte Escape in the Immunodominant HLA-B27-Restricted Epitope in Human Immunodeficiency Virus Type 1 Capsid. J. Virol., 82(11):5594-5605, Jun 2008. PubMed ID: 18385228. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health